Hui Feng, MD, PhD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Pharmacology, Physiology & Biophysics

MD, Beijing Medical University
PhD, University of Georgia
MS, Peking Union Medical College



Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

Diversity, Equity, Inclusion and Accessibility

The Feng laboratory at Boston University (www.bu.edu/zgct) is committed to training the next generation of researchers throughout the world with all ethnicities and cultural backgrounds. Ever since the opening of the laboratory in October 2011, the Feng laboratory has already trained over thirty undergraduate researchers, ten graduate students, thirteen postdoctoral fellows, and nine visiting scientists – many of whom have gone on to pursue a career in academic institutes or industry. Among the fifty-four trainees that Dr. Feng mentored in the past five years, thirty-two are females, nine are underrepresented, and five are disabled. In addition, Dr. Feng has been leading drug discovery efforts as a co-leader for the past ten years in the zebrafish disease model society (ZDMS). Currently, Dr. Feng serves on the board of directors and as the chair of the diversity, equity, and inclusion committee in the ZDMS. She has been an active advocate in promoting trainee diversity and inclusion in her department, school of medicine, and the scientific community at large.

Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




A novel immunotherapeutic strategy for neuronal cancers
07/01/2023 - 06/30/2025 (Key Person / Mentor)
PI: Xiaodan Qin, PhD
Warren Alpert Foundation


Targeting CKLF as an Immunotherapeutic Approach to Treat MYCN-driven High-risk Neuroblastoma
09/15/2022 - 09/14/2024 (PI)
Alex's Lemonade Stand Foundation for Childhood Cancer


Novel family of cellulose acetate fluorescent nanomaterials for bioimaging applications
08/01/2020 - 07/31/2024 (Subcontract PI)
Trustees of Tufts College, Inc National Science Fdn


The Role of DLST in Leukemogenesis
08/07/2018 - 07/31/2024 (PI)
NIH/National Cancer Institute
3R01CA215059-05S1

Personnel Agreement for Research Services of Hui Feng
12/22/2022 - 12/21/2023 (Key Person)
PI: David H. Farb, PhD
Department of Veterans Administration, Bedford


The role of DLST in Treg-mediated immunosuppression of High-risk Neuroblastoma
04/01/2023 - 05/30/2023 (PI)
Alex's Lemonade Stand Foundation for Childhood Cancer


Regulatory Role and Targetability of UFDI in MYC-drlven Leukemia
01/01/2018 - 12/31/2022 (PI)
American Cancer Society, Inc.


Targeting DLST as a Novel Therapeutic Approach for Neuroblastoma
07/01/2018 - 06/30/2019 (PI)
St. Baldrick's Foundation


The Role of DLST in Leukemogenesis
08/15/2017 - 07/31/2018 (PI)
NIH/National Cancer Institute
1R56CA215059-01

Targeting DLST as a Novel Therapeutic Approach for Neuroblastoma
07/01/2017 - 06/30/2018 (PI)
St. Baldrick's Foundation


Showing 10 of 15 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Laroche FJF, Li S, Shen N, Hwang SK, Nguyen G, Yu W, Wong CK, Quinton RJ, Berman JN, Liu CT, Singh A, Ganem NJ, Thiagalingam S, Feng H. S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. Cells. 2023 Mar 23; 12(7).View Related Profiles. PMID: 37048053; PMCID: PMC10093541; DOI: 10.3390/cells12070980;
     
  2. Wang Y, Shen N, Spurlin G, Korm S, Huang S, Anderson NM, Huiting LN, Liu H, Feng H. a-Ketoglutarate-Mediated DNA Demethylation Sustains T-Acute Lymphoblastic Leukemia upon TCA Cycle Targeting. Cancers (Basel). 2022 Jun 16; 14(12).View Related Profiles. PMID: 35740646; PMCID: PMC9221025; DOI: 10.3390/cancers14122983;
     
  3. Kemet C, Hill E, Feng H. Fishing for drugs. Elife. 2022 02 08; 11. PMID: 35133278; PMCID: PMC8824469; DOI: 10.7554/eLife.76632;
     
  4. Shen N, Korm S, Karantanos T, Li D, Zhang X, Ritou E, Xu H, Lam A, English J, Zong WX, Liu CT, Shirihai O, Feng H. DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. Commun Biol. 2021 11 16; 4(1):1289.View Related Profiles. PMID: 34785772; PMCID: PMC8595664; DOI: 10.1038/s42003-021-02805-8;
     
  5. Friedlander JE, Shen N, Zeng A, Korm S, Feng H. Failure to Guard: Mitochondrial Protein Quality Control in Cancer. Int J Mol Sci. 2021 Aug 02; 22(15).View Related Profiles. PMID: 34361072; PMCID: PMC8348654; DOI: 10.3390/ijms22158306;
     
  6. Anderson NM, Qin X, Finan JM, Lam A, Athoe J, Missiaen R, Skuli N, Kennedy A, Saini AS, Tao T, Zhu S, Nissim I, Look AT, Qing G, Simon MC, Feng H. Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma. Cancer Res. 2021 Sep 01; 81(17):4417-4430. PMID: 34233924; PMCID: PMC8577318; DOI: 10.1158/0008-5472.CAN-20-2153;
     
  7. Miao KZ, Kim GY, Meara GK, Qin X, Feng H. Tipping the Scales With Zebrafish to Understand Adaptive Tumor Immunity. Front Cell Dev Biol. 2021; 9:660969.View Related Profiles. PMID: 34095125; PMCID: PMC8173129; DOI: 10.3389/fcell.2021.660969;
     
  8. Zhou Y, Lian H, Shen N, Korm S, Kwok Ping Lam A, Layton O, Huiting LN, Li D, Miao K, Zeng A, Landesman-Bollag E, Seldin DC, Fu H, Hong L, Feng H. The multifaceted role of protein kinase CK2 in high-risk acute lymphoblastic leukemia. Haematologica. 2021 05 01; 106(5):1461-1465.View Related Profiles. PMID: 32817283; PMCID: PMC8094085; DOI: 10.3324/haematol.2020.246918;
     
  9. Shao W, Kilic K, Yin W, Wirak G, Qin X, Feng H, Boas D, Gabel CV, Yi J. Wide field-of-view volumetric imaging by a mesoscopic scanning oblique plane microscopy with switchable objective lenses. Quant Imaging Med Surg. 2021 Mar; 11(3):983-997.View Related Profiles. PMID: 33654671; PMCID: PMC7829172; DOI: 10.21037/qims-20-806;
     
  10. Qin X, Denton WD, Huiting LN, Smith KS, Feng H. Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity. Crit Rev Biochem Mol Biol. 2020 08; 55(4):322-353.View Related Profiles. PMID: 32633575; PMCID: PMC7644137; DOI: 10.1080/10409238.2020.1784085;
     
Showing 10 of 47 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 47 publications over 19 distinct years, with a maximum of 6 publications in 2020 and 2021

YearPublications
19991
20032
20051
20072
20091
20102
20111
20122
20131
20141
20153
20165
20172
20185
20193
20206
20216
20222
20231

2014-2017 St. Baldrick's Foundation: St. Baldrick Career Development Award
2013-2014 Karin Grunebaum Cancer Research Foundation: Grunebaum Faculty Fellowship
2013-2016 Boston University: Ralph Edwards Career Development Professorship
2012-2015 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (R00)
2012-2013 American Cancer Society : American Cancer Society pilot Award
2009-2010 Stahl Family Charitable Foundation: Stahl Family Charitable Foundation Award
2009-2011 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (K99)
2008 Harvard Partners in Health: Partners in Excellence Award
2005-2005 Cancer Research Institute: Postdoctoral Fellowship Award
2005 American Association for Cancer Research: American Association for Cancer Research Award - declined
2005-2008 Leukemia and Lymphoma Society: Special Fellow Award
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Cancer
Cancer Therapeutics
MYC
Tumor Intravasation
Zebrafish

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Education Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map


Feng's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department